High-risk Brugada syndrome: factors associated with arrhythmia recurrence and benefits of epicardial ablation in addition to implantable cardioverter defibrillator implantation
Authors:
- Vincenzo SantinelliVSVincenzo Santinelli
- Giuseppe CiconteGCGiuseppe Ciconte
- Francesco MangusoFMFrancesco Manguso
- Luigi AnastasiaLALuigi Anastasia
- Emanuele MicaglioEmanuele Micaglio
- Gabriele VicedominiGVGabriele Vicedomini
- Beniamino MazzaBMBeniamino Mazza
- Valerio MecarocciVMValerio Mecarocci
- Emanuela T LocatiELEmanuela T Locati
- Antonio BoccellinoABAntonio Boccellino
Open Access
- 28 December 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (1)
Abstract
This study aims to evaluate the prognostic impact of the arrhythmogenic substrate size in symptomatic Brugada syndrome (BrS) as well as to validate the long-term safety and effectiveness of epicardial radiofrequency ablation (RFA) compared with no-RFA group. In this prospective investigational long-term registry study, 257 selected symptomatic BrS patients with implantable cardioverter defibrillator (ICD) implantation were included. Among them, 206 patients underwent epicardial RFA and were monitored for over 5 years post-ablation (RFA group), while 51 patients received only ICD implantation declining RFA. Primary endpoints included risk factors for ventricular fibrillation (VF) events pre-ablation and freedom from VF events post-ablation. In the RFA group, BrS substrates were identified in the epicardial surface of the right ventricle. During the pre-RFA follow-up period (median 27 months), VF episodes and VF storms were experienced by 53 patients. Independent risk factors included substrate size [hazard ratio (HR), 1.13; 95% confidence interval (CI), 1.08–1.18; P < 0.001], aborted cardiac arrest (HR, 2.98; 95% CI, 1.68–5.28; P < 0.001), and SCN5A variants (HR, 2.22; 95% CI, 1.15–4.27; P = 0.017). In the post-RFA follow-up (median 40 months), the RFA group demonstrated superior outcomes compared with no-RFA (P < 0.001) without major procedure-related complications. Our study underscores the role of BrS substrate extent as a crucial prognostic factor for recurrent VF and validates the safety and efficacy of RFA when compared with a no-RFA group. Our findings highlight the importance of ajmaline in guiding epicardial mapping/ablation in symptomatic BrS patients, laying the groundwork for further exploration of non-invasive methods to guide informed clinical decision-making. Upper panel: Independent predictors determined by multivariable Cox analysis along with the respective Kaplan–Meier curves. Middle panel: Epicardial maps of the Brugada syndrome substrate before and after ajmaline infusion pre-ablation, as well as after ajmaline infusion post-ablation. Notably, after the ablation, the substrate is eliminated, even in the presence of ajmaline infusion. Lower panel: Long-term benefits of epicardial ablation in comparison with the no-radiofrequency ablation group.Keywords
Funding Information
- Italian Ministry of Health
This publication has 24 references indexed in Scilit:
- Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS)Heart Rhythm, 2018
- Patients With Brugada Syndrome and Implanted Cardioverter-DefibrillatorsJACC, 2017
- Electrical Substrate Elimination in 135 Consecutive Patients With Brugada SyndromeCirculation: Arrhythmia and Electrophysiology, 2017
- Brugada Syndrome Phenotype Elimination by Epicardial Substrate AblationCirculation: Arrhythmia and Electrophysiology, 2015
- 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathEuropean Heart Journal, 2015
- Implantable Cardioverter-Defibrillator Therapy in Brugada SyndromeJACC, 2015
- Prevention of Ventricular Fibrillation Episodes in Brugada Syndrome by Catheter Ablation Over the Anterior Right Ventricular Outflow Tract EpicardiumCirculation, 2011
- Long-Term Prognosis of Patients Diagnosed With Brugada SyndromeCirculation, 2010
- A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratificationEuropean Heart Journal, 2006
- Mapping and Ablation of Ventricular Fibrillation Associated With Long-QT and Brugada SyndromesCirculation, 2003